GSK's Jemperli (dostarlimab) has been approved for use within NHS Scotland, marking a significant step in the treatment of eligible endometrial cancer patients in the region.
In an important announcement today (April 2), Hutchmed and Innovent jointly revealed the acceptance of their New Drug Application (NDA) in China for the combination of Fruquintinib with Sintilimab.